Cargando…
Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients
Aberrant DNA methylation is considered to play a critical role in the chemoresistance of epithelial ovarian cancer (EOC). In this study, we explored the relationship between hypermethylation of the Mahogunin Ring Finger 1 (MGRN1) gene promoter and primary chemoresistance and clinical outcomes in hig...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277380/ https://www.ncbi.nlm.nih.gov/pubmed/34268111 http://dx.doi.org/10.3389/fonc.2021.659254 |
_version_ | 1783722062076968960 |
---|---|
author | Li, Xiao-fei Sun, Hai-yan Hua, Tian Zhang, Hai-bo Tian, Yun-jie Li, Yan Kang, Shan |
author_facet | Li, Xiao-fei Sun, Hai-yan Hua, Tian Zhang, Hai-bo Tian, Yun-jie Li, Yan Kang, Shan |
author_sort | Li, Xiao-fei |
collection | PubMed |
description | Aberrant DNA methylation is considered to play a critical role in the chemoresistance of epithelial ovarian cancer (EOC). In this study, we explored the relationship between hypermethylation of the Mahogunin Ring Finger 1 (MGRN1) gene promoter and primary chemoresistance and clinical outcomes in high-grade serous ovarian cancer (HGSOC) patients. The MALDI-TOF mass spectrometry assays revealed a strong association between hypermethylation of the MGRN1 upstream region and platinum resistance in HGSOC patients. Spearman’s correlation analysis revealed a significantly negative connection between the methylation level of MGRN1 and its expression in HGSOC. In vitro analysis demonstrated that knockdown of MGRN1 reduced the sensitivity of cells to cisplatin and that expression of EGR1 was significantly decreased in SKOV3 cells with low levels of MGRN1 expression. Similarly, EGR1 mRNA expression was lower in platinum-resistant HGSOC patients and was positively correlated with MGRN1 mRNA expression. Kaplan-Meier analyses showed that high methylation of the MGRN1 promoter region and low expression of MGRN1 were associated with worse survival of HGSOC patients. In multivariable models, low MGRN1 expression was an independent factor predicting poor outcome. Furthermore, low expression of EGR1 was also been confirmed to be significantly related to the poor prognosis of HGSOC patients by Kaplan-Meier. The hypermethylation of the MGRN1 promoter region and low expression of MGRN1 were associated with platinum resistance and poor outcomes in HGSOC patients, probably by altering EGR1 expression. |
format | Online Article Text |
id | pubmed-8277380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82773802021-07-14 Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients Li, Xiao-fei Sun, Hai-yan Hua, Tian Zhang, Hai-bo Tian, Yun-jie Li, Yan Kang, Shan Front Oncol Oncology Aberrant DNA methylation is considered to play a critical role in the chemoresistance of epithelial ovarian cancer (EOC). In this study, we explored the relationship between hypermethylation of the Mahogunin Ring Finger 1 (MGRN1) gene promoter and primary chemoresistance and clinical outcomes in high-grade serous ovarian cancer (HGSOC) patients. The MALDI-TOF mass spectrometry assays revealed a strong association between hypermethylation of the MGRN1 upstream region and platinum resistance in HGSOC patients. Spearman’s correlation analysis revealed a significantly negative connection between the methylation level of MGRN1 and its expression in HGSOC. In vitro analysis demonstrated that knockdown of MGRN1 reduced the sensitivity of cells to cisplatin and that expression of EGR1 was significantly decreased in SKOV3 cells with low levels of MGRN1 expression. Similarly, EGR1 mRNA expression was lower in platinum-resistant HGSOC patients and was positively correlated with MGRN1 mRNA expression. Kaplan-Meier analyses showed that high methylation of the MGRN1 promoter region and low expression of MGRN1 were associated with worse survival of HGSOC patients. In multivariable models, low MGRN1 expression was an independent factor predicting poor outcome. Furthermore, low expression of EGR1 was also been confirmed to be significantly related to the poor prognosis of HGSOC patients by Kaplan-Meier. The hypermethylation of the MGRN1 promoter region and low expression of MGRN1 were associated with platinum resistance and poor outcomes in HGSOC patients, probably by altering EGR1 expression. Frontiers Media S.A. 2021-06-29 /pmc/articles/PMC8277380/ /pubmed/34268111 http://dx.doi.org/10.3389/fonc.2021.659254 Text en Copyright © 2021 Li, Sun, Hua, Zhang, Tian, Li and Kang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Xiao-fei Sun, Hai-yan Hua, Tian Zhang, Hai-bo Tian, Yun-jie Li, Yan Kang, Shan Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients |
title | Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients |
title_full | Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients |
title_fullStr | Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients |
title_full_unstemmed | Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients |
title_short | Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients |
title_sort | promoter methylation of the mgrn1 gene predicts prognosis and response to chemotherapy of high-grade serous ovarian cancer patients |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277380/ https://www.ncbi.nlm.nih.gov/pubmed/34268111 http://dx.doi.org/10.3389/fonc.2021.659254 |
work_keys_str_mv | AT lixiaofei promotermethylationofthemgrn1genepredictsprognosisandresponsetochemotherapyofhighgradeserousovariancancerpatients AT sunhaiyan promotermethylationofthemgrn1genepredictsprognosisandresponsetochemotherapyofhighgradeserousovariancancerpatients AT huatian promotermethylationofthemgrn1genepredictsprognosisandresponsetochemotherapyofhighgradeserousovariancancerpatients AT zhanghaibo promotermethylationofthemgrn1genepredictsprognosisandresponsetochemotherapyofhighgradeserousovariancancerpatients AT tianyunjie promotermethylationofthemgrn1genepredictsprognosisandresponsetochemotherapyofhighgradeserousovariancancerpatients AT liyan promotermethylationofthemgrn1genepredictsprognosisandresponsetochemotherapyofhighgradeserousovariancancerpatients AT kangshan promotermethylationofthemgrn1genepredictsprognosisandresponsetochemotherapyofhighgradeserousovariancancerpatients |